Now Playing
Opinion|Videos|February 22, 2024
Overview of Current mCRC Treatment Landscape
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
4
CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma
5